Triamcinolone acetonide is under clinical development by Clearside BioMedical and currently in Phase II for Non-infectious Uveitis. According to GlobalData, Phase II drugs for Non-infectious Uveitis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Triamcinolone acetonide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Triamcinolone acetonide overview

Triamcinolone acetonide (Xipere) is a corticosteroid, acts as immunosuppressive and anti-inflammatory agent. It is formulated as suspension for suprachoroidal route of administration. Xipere is indicated for the treatment of macular edema associated with uveitis.

Triamcinolone acetonide (CLS1001) is under development for the treatment of non-infectious intermediate, posterior and pan-uveitis, diabetic macular edema, Uveitic Macular Edema and macular edema associated with non-infectious uveitis. The drug is administered as a suprachoroidal injectable suspension and acts by targeting the glucocorticoid receptors. It was also under development for sympathetic ophthalmia, temporal arteritis, ocular inflammatory conditions, branch retinal vein occlusion and central retinal vein occlusion.

Clearside BioMedical overview

Clearside BioMedical (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise of CLS-AX, XIPERE and SCS Microinjector. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight threatening disease often occurs. The company also offers services such as business development, license agreements and contract manufacturing services. Clearside has partners with various pharmaceutical companies for the commercialization and development of its products across the US, Canada, China, Hong Kong, Macau, Taiwan and South Korea, among others. It markets its products across the US. Clearside is headquartered in Alpharetta, Georgia, the US.

For a complete picture of Triamcinolone acetonide’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.